DK1347747T3 - Fremgangsmåde til behandling af submikropartikelsuspensioner af farmaceutiske midler - Google Patents

Fremgangsmåde til behandling af submikropartikelsuspensioner af farmaceutiske midler

Info

Publication number
DK1347747T3
DK1347747T3 DK01998077T DK01998077T DK1347747T3 DK 1347747 T3 DK1347747 T3 DK 1347747T3 DK 01998077 T DK01998077 T DK 01998077T DK 01998077 T DK01998077 T DK 01998077T DK 1347747 T3 DK1347747 T3 DK 1347747T3
Authority
DK
Denmark
Prior art keywords
submicroparticle
suspensions
treating
pharmaceutical agents
solvent
Prior art date
Application number
DK01998077T
Other languages
English (en)
Inventor
Joseph Chung Tak Wong
Sean Brynjelsen
Jane Werling
Rajaram Sriram
James E Kipp
Mark J Doty
Christine L Rebbeck
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/874,637 external-priority patent/US6869617B2/en
Priority claimed from US09/953,979 external-priority patent/US6951656B2/en
Priority claimed from US10/035,821 external-priority patent/US6977085B2/en
Priority claimed from US10/021,692 external-priority patent/US6884436B2/en
Application filed by Baxter Int filed Critical Baxter Int
Application granted granted Critical
Publication of DK1347747T3 publication Critical patent/DK1347747T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
DK01998077T 2000-12-22 2001-12-20 Fremgangsmåde til behandling af submikropartikelsuspensioner af farmaceutiske midler DK1347747T3 (da)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US25816000P 2000-12-22 2000-12-22
US09/874,637 US6869617B2 (en) 2000-12-22 2001-06-05 Microprecipitation method for preparing submicron suspensions
US09/874,499 US7037528B2 (en) 2000-12-22 2001-06-05 Microprecipitation method for preparing submicron suspensions
US09/874,799 US6607784B2 (en) 2000-12-22 2001-06-05 Microprecipitation method for preparing submicron suspensions
US09/953,979 US6951656B2 (en) 2000-12-22 2001-09-17 Microprecipitation method for preparing submicron suspensions
US10/035,821 US6977085B2 (en) 2000-12-22 2001-10-19 Method for preparing submicron suspensions with polymorph control
US10/021,692 US6884436B2 (en) 2000-12-22 2001-12-12 Method for preparing submicron particle suspensions

Publications (1)

Publication Number Publication Date
DK1347747T3 true DK1347747T3 (da) 2006-04-10

Family

ID=27567644

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01998077T DK1347747T3 (da) 2000-12-22 2001-12-20 Fremgangsmåde til behandling af submikropartikelsuspensioner af farmaceutiske midler

Country Status (16)

Country Link
EP (2) EP1347747B1 (da)
JP (1) JP4376518B2 (da)
CN (1) CN100512798C (da)
AT (1) ATE319432T1 (da)
AU (2) AU2002249836B2 (da)
BR (1) BR0116377A (da)
CA (1) CA2431705C (da)
DE (1) DE60117873T2 (da)
DK (1) DK1347747T3 (da)
ES (1) ES2260337T3 (da)
HU (1) HUP0501030A3 (da)
IL (1) IL156310A0 (da)
MX (1) MXPA03005496A (da)
NO (1) NO20032860L (da)
NZ (1) NZ526608A (da)
WO (1) WO2002055059A2 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
AU2002337692B2 (en) 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
US20040028747A1 (en) * 2002-08-06 2004-02-12 Tucker Christopher J. Crystalline drug particles prepared using a controlled precipitation process
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7511079B2 (en) * 2003-03-24 2009-03-31 Baxter International Inc. Methods and apparatuses for the comminution and stabilization of small particles
CN1794975A (zh) * 2003-04-29 2006-06-28 巴克斯特国际公司 使抗微生物的药物有效抗通常认为抗该药物的生物体的制剂
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
BRPI0414970A2 (pt) 2003-06-24 2012-12-11 Baxter Int método para transporte de drogas ao cérebro
EP1646445A4 (en) * 2003-07-18 2007-09-19 Baxter Int METHOD OF MANUFACTURING, USING AND COMPOSING SMALL BALLULAR PARTICLES PRODUCED BY CONTROLLED PHASE SEPARATION
JPWO2005013938A1 (ja) * 2003-08-06 2006-09-28 エーザイ株式会社 薬物超微粒子の製造法及び製造装置
GB0327390D0 (en) * 2003-11-25 2003-12-31 Pfizer Ltd Pharmaceutical formulations
EP1727520A2 (en) * 2003-12-09 2006-12-06 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
CA2554246A1 (en) * 2004-01-29 2005-08-11 Baxter International Inc. Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
DK1731138T3 (da) * 2004-03-31 2016-06-06 Toyama Chemical Co Ltd Fin dispersion af svært opløseligt medikament og fremgangsmåde til fremstilling af denne
AU2005255039A1 (en) 2004-06-15 2005-12-29 Baxter Healthcare S.A. Ex-vivo application of solid microparticulate therapeutic agents
DE102004031538A1 (de) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
MX2007007342A (es) * 2004-12-15 2007-12-11 Elan Pharma Int Ltd Formulaciones de tacrolimus nanoparticuladas.
WO2006101972A2 (en) * 2005-03-17 2006-09-28 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
DE102005053862A1 (de) * 2005-11-04 2007-05-10 Pharmasol Gmbh Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
CA2628630A1 (en) * 2005-11-15 2007-05-24 Baxter International Inc. Compositions of lipoxygenase inhibitors
WO2009111638A1 (en) 2008-03-05 2009-09-11 Baxter International Inc. Compositions and methods for drug delivery
DE102009008478A1 (de) 2009-02-11 2010-08-19 PHAST Gesellschaft für pharmazeutische Qualitätsstandards mbH Vorrichtung und Verfahren zur Herstellung pharmazeutisch hochfeiner Partikel sowie zur Beschichtung solcher Partikel in Mikroreaktoren
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
WO2011116763A1 (de) 2010-03-22 2011-09-29 Mjr Pharmjet Gmbh Verfahren und vorrichtung zur herstellung von mikro- oder nanopartikeln
CN102384973B (zh) * 2011-08-10 2014-09-10 华南理工大学 快速定量检测羟甲基糠醛的免疫层析试纸条及其制备方法
CN102268103B (zh) * 2011-09-02 2013-06-05 中国海洋大学 一种壳聚糖醋酸盐的制备方法
US9248139B2 (en) * 2011-12-21 2016-02-02 Bristol-Myers Squibb Company Co-processing method and formulations for HIV attachment inhibitor prodrug compound and excipients
CN103212079A (zh) * 2013-04-26 2013-07-24 陆媛 一种预防和/或治疗感冒的含服药物组合物及其应用
CN104905262B (zh) * 2015-05-29 2017-12-22 湖北省农业科学院农产品加工与核农技术研究所 一种制备虫草灵芝复合制剂的方法
KR101725508B1 (ko) * 2015-07-31 2017-04-11 국방과학연구소 헥사나이트로스틸벤 입자의 제조 방법과 그 장치
CN105969316B (zh) * 2016-06-03 2020-11-10 宁海德宝立新材料有限公司 一种用于热敷的相变储热复合材料
WO2018023033A1 (en) 2016-07-29 2018-02-01 Western Michigan University Research Foundation Magnetic nanoparticle-based gyroscopic sensor
CN108031142A (zh) * 2017-12-13 2018-05-15 上海合全药物研发有限公司 一种简化的利用湿磨来制备大量微晶种的装置及方法
CN115349630A (zh) * 2022-06-20 2022-11-18 海宁凤鸣叶绿素有限公司 水分散性叶黄素微囊粉的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4606940A (en) * 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
IL86211A (en) * 1987-05-04 1992-03-29 Ciba Geigy Ag Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation
DE69112917T2 (de) * 1990-06-15 1996-05-15 Merck & Co Inc Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse.
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
SE9403846D0 (sv) * 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
FI973804A (fi) * 1997-09-26 1999-03-27 Orion Yhtymae Oy Levosimendaanin oraalisia koostumuksia
JP3696087B2 (ja) * 1997-12-31 2005-09-14 チョンワエ ファーマ コーポレーション イトラコナゾール(itraconazole)経口用製剤及びその製造方法
ATE259220T1 (de) * 1998-05-29 2004-02-15 Skyepharma Canada Inc Gegen hitzeeinwirkung geschützte mikropartikel und verfahren zur terminalen dampfsterilisation derselben
EP1104291B1 (en) * 1998-07-17 2005-09-07 Janssen Pharmaceutica N.V. Pellets having a core coated with an antifungal and a polymer
ATE307808T1 (de) * 1999-03-24 2005-11-15 Scherer Technologies Inc R P Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser
KR100331529B1 (ko) * 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법

Also Published As

Publication number Publication date
WO2002055059A2 (en) 2002-07-18
BR0116377A (pt) 2005-12-13
NZ526608A (en) 2006-06-30
EP1347747B1 (en) 2006-03-08
CN100512798C (zh) 2009-07-15
MXPA03005496A (es) 2004-05-14
AU2006201943A1 (en) 2006-06-01
EP1347747A2 (en) 2003-10-01
HUP0501030A3 (en) 2008-04-28
AU2002249836B2 (en) 2006-12-14
NO20032860L (no) 2003-08-21
ATE319432T1 (de) 2006-03-15
DE60117873D1 (de) 2006-05-04
CA2431705A1 (en) 2002-07-18
EP1642571A2 (en) 2006-04-05
JP4376518B2 (ja) 2009-12-02
WO2002055059A3 (en) 2002-09-06
EP1642571A3 (en) 2007-06-27
HUP0501030A2 (en) 2007-02-28
CA2431705C (en) 2010-10-05
NO20032860D0 (no) 2003-06-20
JP2004538249A (ja) 2004-12-24
DE60117873T2 (de) 2006-08-24
CN1505503A (zh) 2004-06-16
IL156310A0 (en) 2004-01-04
ES2260337T3 (es) 2006-11-01

Similar Documents

Publication Publication Date Title
DK1347747T3 (da) Fremgangsmåde til behandling af submikropartikelsuspensioner af farmaceutiske midler
DE60102899D1 (de) Verfahren zur lösung von glucagon-ähnlichen peptid-1 (glp-1) verbindungen
BR0107425A (pt) Processo para a preparação compostos de derivados de ácido 3-hidróxi picolìnico e uso dos compostos
CY1107198T1 (el) Μεθοδος παραγωγης κρυσταλλου
PT1222173E (pt) Processo para a preparacao de um derivado de 4-trifluorometil-sulfinilpirazole
BRPI9914164B8 (pt) compostos de 3-ciano quinolina
DE60222734D1 (de) Mikropartikel und Verfahren zur deren Herstellung
ATE321758T1 (de) Verbessertes verfahren zur herstellung von verbindungen des benzimidazoltyps
MY126935A (en) Method of stabilizing dye solutions and stabilized dye compositions
DE60007316D1 (de) Verfahren zur mikroverkapselung von wasserlöslichen substanzen
PT1144346E (pt) Processo de preparacao de radicais nitroxido beta-fosforados
NO20016293D0 (no) Fremgangsmåte for fremstilling av astasantin
BR0009453A (pt) Processo para a preparação de um composto
AR019440A1 (es) Una solucion de inyeccion lista para inyectar que contiene carvedilol y un proceso para su produccion
YU59401A (sh) Postupak za proizvodnju alendronske kiseline
ATE275149T1 (de) Verfahren zur herstellung von taxanderivaten
BR0309622A (pt) Composições aquosas lìquidas de derivados de ciclodextrina reativos e um processo de acabamento que usa a referida composição
DE69631602D1 (de) Wässrige dispersionen von polyamiden
DE60232006D1 (de) Rückgewinnung und recycling chiraler weinsäureverbindungen zur racematspaltung
ATE171937T1 (de) Verfahren zur herstellung von diazomethanderivaten
ATE406376T1 (de) Verfahren zur herstellung von finasterid form i
ATE275129T1 (de) Verfahren zur herstellung von aromatischen acylthiocarbonsäurederivaten
DK1214315T5 (da) 1,4-Dihydropyridin-5-carboxylsyreesterderivater og fremgangsmåde til fremstilling af samme
ATE356091T1 (de) Stabilisierte wässrige folsäurezubereitung und verfahren zu dessen herstellung
DE50304869D1 (de) Verfahren zur herstellung einer spezifischen kristallmodifikation von 2-(2-chlor-4-mesyl-benzoyl)-cyclohexan-1,3-dion